Company intelligence / Profile preview

ATP Glycyrrhizinate Center

Shinjuku-ku, Tokyo, Japan

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Minophagen Pharmaceutical is a Japanese pharmaceutical company specialized in the development and manufacture of glycyrrhizin-based therapeutics. The company is most famous for its flagship product, Stronger Neo-Minophagen C (SNMC), which has been used for decades in the treatment of chronic hepatitis and liver diseases. Minophagen focuses on the anti-inflammatory and hepatoprotective properties of glycyrrhizin, a compound derived from licorice root. Beyond hepatology, the company provides treatments for allergic diseases and skin conditions, maintaining a significant presence in the Asian pharmaceutical market.

Therapeutic areas: GastroenterologyImmunologyDermatologyInfectious Diseases
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on ATP Glycyrrhizinate Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP Glycyrrhizinate Center.

Explore the full profile